Evidence map›Paper›PMID 28344668›Full record

ReviewTherapeutic advances in musculoskeletal disease2017

Diabetes and bone health: latest evidence and clinical implications.

Vikram Sundararaghavan, Matthew M Mazur, Brad Evans, Jiayong Liu, Nabil A Ebraheim

Abstract readReview
In one paragraph

Review in Therapeutic advances in musculoskeletal disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed.

  1. Trial
  2. Article
  3. Bone Organoids: A Novel Tool for Modeling and Managing Skeletal Disorders in Diabetes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. The Effect of Diabetes Mellitus on Mandibular Growth.Turkish journal of orthodontics · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vikram SundararaghavanDepartment of Orthopaedic Surgery, University of Toledo Medical Center, Toledo, OH, USA.
Matthew M MazurDepartment of Orthopaedic Surgery, University of Toledo Medical Center, Toledo, OH, USA.
Brad EvansDepartment of Orthopaedic Surgery, University of Toledo Medical Center, Toledo, OH, USA.
Jiayong LiuDepartment of Orthopaedic Surgery, University of Toledo Medical Center, 3065 Arlington Avenue, Toledo, OH 43614, USA.
Nabil A EbraheimDepartment of Orthopaedic Surgery, University of Toledo Medical Center, Toledo, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the prevalence of diabetes is increasing worldwide, research on some of the lesser-known effects, including impaired bone health, are gaining a lot of attention. The two most common forms of diabetes are type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). These two differ in their physiology, with T1DM stemming from an inability to produce insulin, and T2DM involving an insufficient response to the insulin that is produced. This review aims to highlight the most current information regarding diabetes as it relates to bone health. It looks at biochemical changes that characterize diabetic bone; notably increased adiposity, altered bone metabolism, and variations in bone mineral density (BMD). Then several hypotheses are analyzed, concerning how these changes may be detrimental to the highly orchestrated processes that are involved in bone formation and turnover, and ultimately result in the distinguishing features of diabetic bone. The review proceeds by explaining the effects of antidiabetes medications on bone health, then highlighting several ways that diabetes can play a part in other clinical treatment outcomes. With diabetes negatively affecting bone health and creating other clinical problems, and its treatment options potentiating these effects, physicians should consider the use of anti-osteoporotic drugs to supplement standard anti-diabetes medications in patients suffering with diabetic bone loss.

Indexed as

bone healthbone lossbone turnoverdiabetesmetabolismtype 1type 2

Identifiers

PMID28344668
PMCPMC5349336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.